| Trial registration number
|
NCT05268419 |
Full text link
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05268419
|
First author
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Shaghayegh Haghju Javanmard
|
Contact
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Not reported
|
Registration date
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
2022-03-07
|
Recruitment status
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Completed
|
Study design
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
positive rt-pcr test less than seven days from onset of symptoms
agreeing to implement the plan in the form of informed consent
age over 12 years
not pregnant
no history of asthma
alcoholism
epilepsy
no contraindications to ethanol
|
Exclusion criteria
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
pregnancy
intolerance to inhaled ethanol
hypersensitivity
allergies to ethanol
use of drugs that interact with ethanol
partial or incomplete treatment
|
Number of arms
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Ali Amoushahi
|
Inclusion age min
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
12
|
Inclusion age max
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
77
|
Countries
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Iran;Islamic Republic of
|
Type of patients
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
No restriction on type of patients
|
Severity scale
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
0: No restriction on type of patients
|
Total sample size
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
150
|
primary outcome
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Global Symptomatic Score;Global Symptomatic Score;Global Symptomatic Score;Global Symptomatic Score
|
Notes
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
Phase 3
|
Arms
Last imported at : March 8, 2022, 10:30 p.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 485, "treatment_name": "Ethanol", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|